Loading…
Loading…
See exactly how PVI's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for PVI and 80,000+ other tickers.
The Invesco Floating Rate Municipal Income ETF (PVI) aims to replicate the performance of the ICE US Municipal AMT-Free VRDO Constrained Index. This Fund typically allocates a minimum of 80% of its total assets to U.S. dollar-denominated, tax-exempt variable rate demand obligations (VRDOs). The benchmark Index itself monitors tax-free VRDOs publicly issued by U.S. states, territories, and their various political subdivisions, all of which feature interest rates that are adjusted daily, weekly, or monthly. Rather than acquiring every constituent security of the Index, the Fund utilizes a…
Commercial adoption of the LIBERTY System by sites that participated in the clinical trial serves as a strong validation of the value it brings to everyday practice The Company will attend the Annual Global Embolization Symposium & Technologies (GEST), a Premier Medical Conference in New York City that attracts over 1,000 global experts across key target call points HINGHAM, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY Endovascular Robotic System, which is experiencing strong interest from physicians and hospital executives following the commencement of the Full Market Release of LIBERTY at the recent Society of Interventional Radiology (SIR) annual meeting, has since won accounts in key sales territories, including two accounts that participated in the ACCESS-PVI pivotal clinical trial.
Being Published in the Journal of Vascular and Interventional Radiology, a Premier Peer-Reviewed Journal, Speaks to the Quality and Impact of the Study Company Remains Focused on Expanding Evidence-Based Data to Support Broader Commercial Adoption of the LIBERTY System HINGHAM, Mass., March 24, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, which is already garnering medical and industry attention, today announced the publication of an article in the Journal of Vascular and Interventional Radiology (JVIR), titled “In Vivo Evaluation of a Disposable Endovascular Robotic System for Arterial Peripheral Vascular Interventions: A Multicenter Feasibility Study.
BOSTON--(BUSINESS WIRE)-- #AFSymposium2026--Vektor Medical, a medical technology company transforming cardiac arrhythmia care, today announced its participation in AF Symposium 2026, taking place February 5–8 in Boston, where new clinical data and physician experiences will highlight how vMap can help improve procedural efficiency, enhance arrhythmia termination, and help enable post-ablation non-inducibility. At this year's meeting, a featured study titled “High Procedural Efficiency and Arrhythmia Non-Inducibil.
Company Reaffirms Expected Timing of FDA Decision With Respect to 510(K) Clearance of LIBERTY® During the Current Second Quarter Company Reaffirms Expected Timing of FDA Decision With Respect to 510(K) Clearance of LIBERTY® During the Current Second Quarter
MBOT announces the successful completion of its ACCESS-PVI clinical trial for the LIBERTY Endovascular Robotic Surgical System, paving the way for FDA submission.